Hims & Hers Health (NYSE:HIMS) Reaches New 12-Month High on Analyst Upgrade

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) hit a new 52-week high on Monday after TD Cowen raised their price target on the stock from $25.00 to $28.00. TD Cowen currently has a buy rating on the stock. Hims & Hers Health traded as high as $26.49 and last traded at $25.90, with a volume of 2347831 shares. The stock had previously closed at $23.41.

A number of other brokerages also recently issued reports on HIMS. Needham & Company LLC started coverage on Hims & Hers Health in a report on Thursday, August 22nd. They set a "buy" rating and a $24.00 price target for the company. Piper Sandler reiterated a "neutral" rating and issued a $21.00 price target (up from $18.00) on shares of Hims & Hers Health in a research note on Tuesday, November 5th. Truist Financial boosted their price objective on shares of Hims & Hers Health from $13.00 to $23.00 and gave the stock a "hold" rating in a research report on Thursday, July 18th. Deutsche Bank Aktiengesellschaft increased their target price on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a "hold" rating in a research report on Wednesday, November 6th. Finally, Imperial Capital cut shares of Hims & Hers Health from an "outperform" rating to an "in-line" rating in a research report on Friday, August 9th. Eight research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $21.21.

Insiders Place Their Bets

In other news, CFO Oluyemi Okupe sold 269,739 shares of the business's stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $20.31, for a total value of $5,478,399.09. Following the transaction, the chief financial officer now owns 145,763 shares of the company's stock, valued at approximately $2,960,446.53. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, CFO Oluyemi Okupe sold 269,739 shares of Hims & Hers Health stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $20.31, for a total value of $5,478,399.09. Following the sale, the chief financial officer now owns 145,763 shares of the company's stock, valued at $2,960,446.53. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Soleil Boughton sold 2,345 shares of the stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $14.65, for a total transaction of $34,354.25. Following the transaction, the insider now directly owns 159,796 shares of the company's stock, valued at $2,341,011.40. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 854,547 shares of company stock valued at $15,987,230. 17.71% of the stock is owned by company insiders.

Institutional Trading of Hims & Hers Health

Institutional investors have recently modified their holdings of the business. Nisa Investment Advisors LLC boosted its holdings in Hims & Hers Health by 679.2% during the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company's stock worth $37,000 after buying an additional 1,603 shares in the last quarter. Quest Partners LLC boosted its stake in shares of Hims & Hers Health by 5,944.1% during the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company's stock worth $72,000 after acquiring an additional 3,507 shares in the last quarter. CWM LLC boosted its stake in shares of Hims & Hers Health by 21.4% during the 3rd quarter. CWM LLC now owns 5,982 shares of the company's stock worth $110,000 after acquiring an additional 1,054 shares in the last quarter. Van ECK Associates Corp purchased a new position in Hims & Hers Health in the 2nd quarter valued at approximately $111,000. Finally, Amalgamated Bank raised its holdings in Hims & Hers Health by 55.9% during the second quarter. Amalgamated Bank now owns 6,566 shares of the company's stock worth $133,000 after purchasing an additional 2,354 shares during the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Price Performance

The company has a market capitalization of $5.99 billion, a PE ratio of 62.77 and a beta of 1.06. The stock has a 50-day simple moving average of $18.75 and a 200 day simple moving average of $18.49.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. During the same period in the previous year, the firm earned ($0.04) EPS. The business's revenue for the quarter was up 77.1% compared to the same quarter last year. As a group, research analysts predict that Hims & Hers Health, Inc. will post 0.25 EPS for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.